High Quality Cinnarizine Capsule, Cerebral Arteriosclerosis, Cerebral Thrombosis Suppliers in China

Home > Products > Anti-Cancer Drug > Anticancer Drug 50mg Free Acid Ciclofosfamida/Cyclophosphamid/Cyclophosphamidum/Cytophosphane Tablets

Anticancer Drug 50mg Free Acid Ciclofosfamida/Cyclophosphamid/Cyclophosphamidum/Cytophosphane Tablets

Basic Info

Model No.:  cyc-1

Product Description



Model NO.: cyc-1


Usage Mode: For oral administration


State: Solid


Type: Biological Products


Color: as Your Requirement


Specification: 50mg


HS Code: 3001200090




Application: Internal Medicine


Suitable for: Elderly, Adult


Shape: Tablet


Pharmaceutical Technology: Chemical Synthesis


Trademark: OEM


Origin: China


Indications and Usage for Cyclophosphamidum

Malignant Diseases

Cyclophosphamidum Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to Cyclophosphamidum treatment:

1.

Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma.

2.

Multiple myeloma.

3.

Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (Cyclophosphamidum given during remission is effective in prolonging its duration).

4.

Mycosis fungoides (advanced disease).

5.

Neuroblastoma (disseminated disease).

6.

Adenocarcinoma of the ovary.

7.

Retinoblastoma.

8.

Carcinoma of the breast.

Nonmalignant Disease

Biopsy Proven "Minimal Change" Nephrotic Syndrome in Children:

Cyclophosphamidum Tablets USP, 25 mg and 50 mg are useful in carefully selected cases of biopsy proven "minimal change" nephrotic syndrome in children but should not be used as primary therapy. In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, Cyclophosphamidum may induce a remission. Cyclophosphamidum is not indicated for the nephrotic syndrome in adults or for any other renal disease.

Contraindications

Continued use of Cyclophosphamidum is contraindicated in patients with severely depressed bone marrow function. Cyclophosphamidum is contraindicated in patients who have demonstrated a previous hypersensitivity to it (see WARNINGS and PRECAUTIONS).



Amenorrhea associated with decreased estrogen and increased gonadotropin secretion develops in a significant proportion of women treated with Cyclophosphamidum. Affected patients generally resume regular menses within a few months after cessation of therapy. Girls treated with Cyclophosphamidum during prepubescence generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged Cyclophosphamidum treatment in late prepubescence has been reported. Girls treated with Cyclophosphamidum during prepubescence subsequently have conceived.

Men treated with may develop oligospermia or azoospermia associated with increased gonadotropin but normal testosterone secretion. Sexual potency and libido are unimpaired in these patients. Boys treated with Cyclophosphamidum during prepubescence develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamidum-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy. Men temporarily rendered sterile by Cyclophosphamidum have subsequently fathered normal children.



Anaphylactic reactions have been reported; death has also been reported in association with this event. Possible cross-sensitivity with other alkylating agents has been reported.

Anticancer Drug 50mg Free Acid Ciclofosfamida/Cyclophosphamid/Cyclophosphamidum/Cytophosphane Tablets

Contact us if you need more details on Cytophosphane Tablets. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Anticancer Drug、Nasopharynx Cancer. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Anti-Cancer Drug